跳至主要内容
临床试验/EUCTR2012-002777-56-IT
EUCTR2012-002777-56-IT进行中(未招募)不适用

Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study

ROCHE0 个研究点开始时间: 2012年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
ROCHE

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Signature of the informed consent form for participation in this study;
  • Previous participation in study ML18253;
  • Administration of at least one dose of the study drug during ML18253 study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Patients not satisfying the above inclusion criteria will not be enrolled in the study.

研究者

发起方
ROCHE

相似试验

尚未招募
Unknown
A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world settingextensive-stage small cell lung cancer
JPRN-UMIN000053134Shinshu University350
已完成
不适用
A cross-sectional study to assess the effects of interprofessional working and inter-unit cooperation on the employee satisfaction in Japanese tertiary hospitals.
JPRN-UMIN000016263Department of education and research in family and community medicine, Mie University Graduate School of Medicine.5,000
招募中
不适用
A multicenter study of the clinical evaluations of inhaled corticosteroids for bronchial asthma.asthma
JPRN-UMIN000003148Kagoshima university hospital200
进行中(未招募)
不适用
An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyelitis vaccine (REVAXIS®) in subjects of 40 years of age or older without a previous diphtheria and tetanus-containing booster within the last 20 yearsEvaluation of the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyelitis vaccine (REVAXIS®).The MedDRA term corresponding to classification code 10069577 is Pertussis immunisation.MedDRA version: 13.1Level: PTClassification code 10054129Term: Diphtheria immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: LLTClassification code 10053386Term: Poliomyelitis vaccineSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: PTClassification code 10069577Term: Pertussis immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: PTClassification code 10054131Term: Tetanus immunisationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2010-023086-21-DESanofi Pasteur MSD S.N.C.335
已完成
不适用
A multicenter prospective cohort study utilizing ICF in elderly patients with heart failureSymptomatic heart failure
JPRN-UMIN000045315Hiroshima University Hospital50